Cycle Pharmaceuticals Receives FDA Approval and Launches Ketorolac Tromethamine Injection 30mg/mL in the U.S.

By | September 19th, 2017|Generics, News|

Cycle Pharmaceuticals Partners with Cardinal as the Logistic Provider for Nityr in U.S.

By | August 7th, 2017|News, Nityr|

Cycle Pharmaceuticals Partners with Diplomat to Dispense NityrTM in U.S.

By | August 3rd, 2017|News, Nityr|

Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1

By | August 1st, 2017|News, Nityr|

First recommendation for HT-1 treatment in Quebec by INESSS

By | June 2nd, 2017|News|

CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular Disease

By | December 19th, 2016|News|

CYCLE Pharmaceuticals Nitisinone Tablets Approved by Health Canada for the Treatment of HT-1

By | November 8th, 2016|News|

Cycle Pharmaceuticals and the Cystic Fibrosis Trust partnership

By | September 22nd, 2016|News|

Antonio Benedetti appointed as CEO of Cycle Pharmaceuticals

By | January 11th, 2016|News|